A small company can now advance its psychedelic into phase 3. Here’s why that matters to other psychedelic biotechs. A small ...

GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant ...

The FDA lifted its clinical hold on GH Research's GH001 after Phase 2b data showed rapid, durable benefits in ...

Shares of Cyclerion Therapeutics climbed after the company entered an agreement to integrate Medsteer's technology into its lead program in development for treatment-resistant depression. The stock ...

Cyclerion Therapeutics entered an agreement to integrate Medsteer's technology into CYC-126, its lead program in development for treatment-resistant depression.

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial. Spravato ...

Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, and long-term safety data to reduce costly treatment-resistant depression.

Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer ...

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in patients with depressive episodes that didn’t respond to ...

Moment of Clarity has published a new educational resource on insurance coverage considerations for transcranial magnetic ...

Treatment-resistant (refractory) depression has been a fertile topic for several decades (e.g., Freyhan, 1978; Nierenberg & Amsterdam, 1990; Voineskos, 2020). Unfortunately, as noted by Voineskos, ...

Share on Pinterest New research finds that ketamine may be a more effective treatment for severe depression than electroconvulsive therapy. damircudic/Getty Images A new study compares ketamine with ...